M van Lettow1, A K Chan2, A S Ginsburg3, H Tweya3, D Gareta3, J Njala4, H Kanyerere5, S Phiri3, I Idana5. 1. Dignitas International, Zomba, Malawi ; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 2. Dignitas International, Zomba, Malawi ; Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. 3. The Lighthouse Trust, Lilongwe, Malawi. 4. Department of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi. 5. National Tuberculosis Programme, Lilongwe, Malawi.
Abstract
SETTING: Uptake of antiretroviral therapy (ART) in patients co-infected with tuberculosis (TB) and the human immunodeficiency virus (HIV) has historically been low in Malawi. In response, the National TB Programme piloted the initiation of ART 2 weeks after initiation of TB treatment in 2008-2009, a change from the prior policy of 2 months. OBJECTIVE: To determine at programme level if earlier initiation of ART in co-infected patients receiving TB treatment will increase the uptake and continuation of ART. DESIGN: A prospective observational pilot programme evaluation using routinely collected monitoring data from the first two sites with integrated TB-HIV services in Malawi. RESULTS: There was wide variability in the ART start time before and after the policy change. Before the policy change, 16% of patients initiated ART by 3 months compared to 24% after the policy change (P < 0.001). The proportion of all co-infected patients on ART increased from 32% before the policy change to 39% after (P < 0.001). Earlier initiation of ART did not increase the occurrence of side effects and did not reduce adherence to TB treatment. CONCLUSION: Earlier initiation of ART in co-infected patients receiving TB treatment improved the uptake and continuation of ART. Malawi ART guidelines in 2011 were changed from initiating ART after 2 months to as soon as possible after starting anti-tuberculosis treatment.
SETTING: Uptake of antiretroviral therapy (ART) in patients co-infected with tuberculosis (TB) and the human immunodeficiency virus (HIV) has historically been low in Malawi. In response, the National TB Programme piloted the initiation of ART 2 weeks after initiation of TB treatment in 2008-2009, a change from the prior policy of 2 months. OBJECTIVE: To determine at programme level if earlier initiation of ART in co-infected patients receiving TB treatment will increase the uptake and continuation of ART. DESIGN: A prospective observational pilot programme evaluation using routinely collected monitoring data from the first two sites with integrated TB-HIV services in Malawi. RESULTS: There was wide variability in the ART start time before and after the policy change. Before the policy change, 16% of patients initiated ART by 3 months compared to 24% after the policy change (P < 0.001). The proportion of all co-infected patients on ART increased from 32% before the policy change to 39% after (P < 0.001). Earlier initiation of ART did not increase the occurrence of side effects and did not reduce adherence to TB treatment. CONCLUSION: Earlier initiation of ART in co-infected patients receiving TB treatment improved the uptake and continuation of ART. Malawi ART guidelines in 2011 were changed from initiating ART after 2 months to as soon as possible after starting anti-tuberculosis treatment.
Entities:
Keywords:
ART initiation; Malawi; TB-HIV co-infection
Authors: Maria Velasco; Virgilio Castilla; José Sanz; Gabriel Gaspar; Emilia Condes; Carlos Barros; Miguel Cervero; Rafael Torres; Carlos Guijarro Journal: J Acquir Immune Defic Syndr Date: 2009-02-01 Impact factor: 3.731
Authors: R A M Breen; R F Miller; T Gorsuch; C J Smith; A Schwenk; W Holmes; J Ballinger; L Swaden; M A Johnson; I Cropley; M C I Lipman Journal: Thorax Date: 2006-07-14 Impact factor: 9.139
Authors: Ronan A M Breen; R F Miller; T Gorsuch; C J Smith; J Ainsworth; J Ballinger; L Swaden; I Cropley; M A Johnson; M C I Lipman Journal: J Infect Dis Date: 2006-04-04 Impact factor: 5.226
Authors: R Zachariah; M Fitzgerald; M Massaquoi; A Acabu; D Chilomo; F M L Salaniponi; A D Harries Journal: Int J Tuberc Lung Dis Date: 2007-08 Impact factor: 2.373
Authors: Tara Vijayan; Fred C Semitala; Nicholas Matsiko; Patrick Elyanu; Jennifer Namusobya; Diane V Havlir; Moses Kamya; Elvin H Geng Journal: Clin Infect Dis Date: 2013-09-24 Impact factor: 9.079
Authors: Matthew Arentz; Patricia Pavlinac; Michael E Kimerling; David J Horne; Dennis Falzon; Holger J Schünemann; Sarah Royce; Keertan Dheda; Judd L Walson Journal: PLoS One Date: 2012-11-05 Impact factor: 3.240